Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study
Both Q4W and Q6W NTZ regimens provided comparable safety and effectiveness in RRMS patients, effectively preventing relapses, AEs, disability progression, and occurrence of enlarged/new T2 lesions. In addition, no patient developed PML.
Authors
- Samar Farouk Ahmed (ORCID: https://orcid.org/0000-0002-9026-9219)
- Raed Alroughani
- Jasem Al–Hashel
Institutions
- Amiri Hospital (KW)
- Kuwait University (KW)
- Ibn Sina Hospital (KW)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.msard.2025.106297
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- AstraZeneca
- Sanofi
- Biogen